메뉴 건너뛰기




Volumn 50, Issue 6, 2012, Pages 363-372

Update on the management of ulcerative colitis

Author keywords

Inflammatory bowel diseases; Therapeutics; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ABATACEPT; ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; BASILIXIMAB; BRIAKINUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DACLIZUMAB; FONTOLIZUMAB; GANCICLOVIR; GASTROINTESTINAL AGENT; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PENTAMIDINE; PLACEBO; PREDNISOLONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STEROID; TACROLIMUS; TOCILIZUMAB; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; USTEKINUMAB; VEDOLIZUMAB; VISILIZUMAB;

EID: 84865680988     PISSN: 00446025     EISSN: 17359694     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (14)

References (70)
  • 3
    • 34247504544 scopus 로고    scopus 로고
    • Risks and benefits of biologic therapy for inflammatory bowel diseases
    • D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007;56(5):725-32.
    • (2007) Gut , vol.56 , Issue.5 , pp. 725-732
    • D'Haens, G.1
  • 4
    • 77958010047 scopus 로고    scopus 로고
    • What are the guidelines for using biologics in pediatric patients?
    • de Zoeten E, Mamula P. What are the guidelines for using biologics in pediatric patients? Inflamm Bowel Dis 2008;14 Suppl 2:S259-61.
    • (2008) Inflamm Bowel Dis , vol.14 , Issue.SUPPL. 2
    • de Zoeten, E.1    Mamula, P.2
  • 8
    • 4344602852 scopus 로고    scopus 로고
    • Guidelines for the management of inflammatory bowel disease in adults
    • Carter M, Lobo A, Travis S. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(suppl 5):V1-V16.
    • (2004) Gut , vol.53 , Issue.SUPPL. 5
    • Carter, M.1    Lobo, A.2    Travis, S.3
  • 9
    • 33750105599 scopus 로고    scopus 로고
    • Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis
    • Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.Cochrane Database Syst Rev 2006;(3):CD005112.
    • (2006) Cochrane Database Syst Rev , Issue.3
    • Lawson, M.M.1    Thomas, A.G.2    Akobeng, A.K.3
  • 10
    • 0036278519 scopus 로고    scopus 로고
    • The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30 year review
    • Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50(4):485-9.
    • (2002) Gut , vol.50 , Issue.4 , pp. 485-489
    • Fraser, A.G.1    Orchard, T.R.2    Jewell, D.P.3
  • 11
    • 29244457275 scopus 로고    scopus 로고
    • Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis
    • Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55(1): 47-53.
    • (2006) Gut , vol.55 , Issue.1 , pp. 47-53
    • Ardizzone, S.1    Maconi, G.2    Russo, A.3    Imbesi, V.4    Colombo, E.5    Bianchi Porro, G.6
  • 14
    • 79953778809 scopus 로고    scopus 로고
    • Efficacy of immunosuppressive therapy for inflammatory bowel disease: A systematic review and meta-analysis
    • Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106(4):630-42.
    • (2011) Am J Gastroenterol , vol.106 , Issue.4 , pp. 630-642
    • Khan, K.J.1    Dubinsky, M.C.2    Ford, A.C.3    Ullman, T.A.4    Talley, N.J.5    Moayyedi, P.6
  • 15
    • 45549107735 scopus 로고    scopus 로고
    • Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: Prospective, long-term, follow-up study of 394 patients
    • Gisbert JP, Niño P, Cara C, Rodrigo L. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther 2008;28(2):228-38.
    • (2008) Aliment Pharmacol Ther , vol.28 , Issue.2 , pp. 228-238
    • Gisbert, J.P.1    Niño, P.2    Cara, C.3    Rodrigo, L.4
  • 16
    • 3142660552 scopus 로고    scopus 로고
    • A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroiddependent ulcerative colitis
    • Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, Triadaphyllou G. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroiddependent ulcerative colitis. Am J Gastroenterol 2004;99(6):1122-8.
    • (2004) Am J Gastroenterol , vol.99 , Issue.6 , pp. 1122-1128
    • Mantzaris, G.J.1    Sfakianakis, M.2    Archavlis, E.3    Petraki, K.4    Christidou, A.5    Karagiannidis, A.6    Triadaphyllou, G.7
  • 17
    • 27744461917 scopus 로고    scopus 로고
    • Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease
    • Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005;20(8):1149-57.
    • (2005) J Gastroenterol Hepatol , vol.20 , Issue.8 , pp. 1149-1157
    • Gearry, R.B.1    Barclay, M.L.2
  • 18
    • 78249243846 scopus 로고    scopus 로고
    • The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease
    • Ban H, Andoh A, Imaeda H, Kobori A, Bamba S, Tsujikawa T, Sasaki M, Saito Y, Fujiyama Y. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol 2010;45(10):1014-21.
    • (2010) J Gastroenterol , vol.45 , Issue.10 , pp. 1014-1021
    • Ban, H.1    Andoh, A.2    Imaeda, H.3    Kobori, A.4    Bamba, S.5    Tsujikawa, T.6    Sasaki, M.7    Saito, Y.8    Fujiyama, Y.9
  • 19
    • 22644446331 scopus 로고    scopus 로고
    • Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
    • Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54(8):1121-5.
    • (2005) Gut , vol.54 , Issue.8 , pp. 1121-1125
    • Kandiel, A.1    Fraser, A.G.2    Korelitz, B.I.3    Brensinger, C.4    Lewis, J.D.5
  • 20
    • 27744589897 scopus 로고    scopus 로고
    • Review article: How and when to use ciclosporin in ulcerative colitis
    • Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005;22(10):907-16.
    • (2005) Aliment Pharmacol Ther , vol.22 , Issue.10 , pp. 907-916
    • Durai, D.1    Hawthorne, A.B.2
  • 21
    • 0037301721 scopus 로고    scopus 로고
    • Cyclosporin for refractory ulcerative colitis
    • Loftus CG, Loftus EV Jr, Sandborn WJ. Cyclosporin for refractory ulcerative colitis. Gut 2003;52(2):172-3.
    • (2003) Gut , vol.52 , Issue.2 , pp. 172-173
    • Loftus, C.G.1    Loftus Jr., E.V.2    Sandborn, W.J.3
  • 22
    • 0001902429 scopus 로고
    • A critical review of cyclosporin therapy in inflammatory bowel disease
    • Sandborn W. A critical review of cyclosporin therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995;1:48-63.
    • (1995) Inflamm Bowel Dis , vol.1 , pp. 48-63
    • Sandborn, W.1
  • 23
    • 0027252555 scopus 로고
    • Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids
    • Actis GC, Ottobrelli A, Pera A, Barletti C, Ponti V, Pinna-Pintor M, Verme G. Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol 1993;17(1):10-3.
    • (1993) J Clin Gastroenterol , vol.17 , Issue.1 , pp. 10-13
    • Actis, G.C.1    Ottobrelli, A.2    Pera, A.3    Barletti, C.4    Ponti, V.5    Pinna-Pintor, M.6    Verme, G.7
  • 26
    • 33644869450 scopus 로고    scopus 로고
    • American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease
    • American Gastroenterological Association
    • Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130(3):940-87.
    • (2006) Gastroenterology , vol.130 , Issue.3 , pp. 940-987
    • Lichtenstein, G.R.1    Abreu, M.T.2    Cohen, R.3    Tremaine, W.4
  • 28
    • 34247181314 scopus 로고    scopus 로고
    • Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: A long-term retrospective cohort study
    • Actis GC, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 2007;7:13.
    • (2007) BMC Gastroenterol , vol.7 , pp. 13
    • Actis, G.C.1    Fadda, M.2    David, E.3    Sapino, A.4
  • 33
    • 14644394897 scopus 로고    scopus 로고
    • Review article: Monitoring of immunomodulators in inflammatory bowel disease
    • Aberra FN, Lichtenstein GR. Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther 2005;21(4):307-19.
    • (2005) Aliment Pharmacol Ther , vol.21 , Issue.4 , pp. 307-319
    • Aberra, F.N.1    Lichtenstein, G.R.2
  • 37
    • 33747790601 scopus 로고    scopus 로고
    • A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis
    • Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55(9):1255-62.
    • (2006) Gut , vol.55 , Issue.9 , pp. 1255-1262
    • Ogata, H.1    Matsui, T.2    Nakamura, M.3    Iida, M.4    Takazoe, M.5    Suzuki, Y.6    Hibi, T.7
  • 38
    • 54049133777 scopus 로고    scopus 로고
    • Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis
    • Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 2008;(3):CD007216.
    • (2008) Cochrane Database Syst Rev , vol.3
    • Baumgart, D.C.1    Macdonald, J.K.2    Feagan, B.3
  • 39
    • 33646582645 scopus 로고    scopus 로고
    • Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease: A long-term follow-up
    • Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease: a long-term follow-up. Am J Gastroenterol 2006;101(5):1048-56.
    • (2006) Am J Gastroenterol , vol.101 , Issue.5 , pp. 1048-1056
    • Baumgart, D.C.1    Pintoffl, J.P.2    Sturm, A.3    Wiedenmann, B.4    Dignass, A.U.5
  • 41
    • 79954449661 scopus 로고    scopus 로고
    • The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease
    • Naganuma M, Fujii T, Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol 2011;46(2):129-37.
    • (2011) J Gastroenterol , vol.46 , Issue.2 , pp. 129-137
    • Naganuma, M.1    Fujii, T.2    Watanabe, M.3
  • 43
    • 0024517127 scopus 로고
    • Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease
    • Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110(5):353-6.
    • (1989) Ann Intern Med , vol.110 , Issue.5 , pp. 353-356
    • Kozarek, R.A.1    Patterson, D.J.2    Gelfand, M.D.3    Botoman, V.A.4    Ball, T.J.5    Wilske, K.R.6
  • 44
    • 0033679444 scopus 로고    scopus 로고
    • 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroiddependent inflammatory bowel disease
    • Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroiddependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12(11):1227-33.
    • (2000) Eur J Gastroenterol Hepatol , vol.12 , Issue.11 , pp. 1227-1233
    • Mate-Jimenez, J.1    Hermida, C.2    Cantero-Perona, J.3    Moreno-Otero, R.4
  • 45
    • 0036791285 scopus 로고    scopus 로고
    • Azathioprine or methotrexate in the treatment of patients with steroiddependent or steroid-resistant ulcerative colitis: Results of an open-label study on efficacy and tolerability in inducing and maintaining remission
    • Paoluzi OA, Pica R, Marcheggiano A, Crispino P, Iacopini F, Iannoni C, Rivera M, Paoluzi P. Azathioprine or methotrexate in the treatment of patients with steroiddependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002;16(10):1751-9.
    • (2002) Aliment Pharmacol Ther , vol.16 , Issue.10 , pp. 1751-1759
    • Paoluzi, O.A.1    Pica, R.2    Marcheggiano, A.3    Crispino, P.4    Iacopini, F.5    Iannoni, C.6    Rivera, M.7    Paoluzi, P.8
  • 46
    • 68949209778 scopus 로고    scopus 로고
    • Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/ mercaptopurine
    • Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, McCartney SA, Lindsay JO, Bloom SL. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/ mercaptopurine. Aliment Pharmacol Ther 2009; 30(6):614-20.
    • (2009) Aliment Pharmacol Ther , vol.30 , Issue.6 , pp. 614-620
    • Wahed, M.1    Louis-Auguste, J.R.2    Baxter, L.M.3    Limdi, J.K.4    McCartney, S.A.5    Lindsay, J.O.6    Bloom, S.L.7
  • 47
    • 0023874002 scopus 로고
    • Methotrexate pneumonitis in rheumatoid arthritis: Potential risk factors. Four case reports and a review of the literature
    • Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987;14(6):1164-71.
    • (1987) J Rheumatol , vol.14 , Issue.6 , pp. 1164-1171
    • Searles, G.1    McKendry, R.J.2
  • 48
    • 67549107120 scopus 로고    scopus 로고
    • Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic literature research
    • Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68(7):1100-4.
    • (2009) Ann Rheum Dis , vol.68 , Issue.7 , pp. 1100-1104
    • Salliot, C.1    van der Heijde, D.2
  • 49
    • 0029874331 scopus 로고    scopus 로고
    • A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation
    • Behrend M. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation. Clin Nephrol 1996;45(5):336-41.
    • (1996) Clin Nephrol , vol.45 , Issue.5 , pp. 336-341
    • Behrend, M.1
  • 53
    • 64549087951 scopus 로고    scopus 로고
    • Use of mycophenolate mofetil in inflammatory bowel disease
    • Tan T, Lawrance IC. Use of mycophenolate mofetil in inflammatory bowel disease. World J Gastroenterol 2009;15(13):1594-9.
    • (2009) World J Gastroenterol , vol.15 , Issue.13 , pp. 1594-1599
    • Tan, T.1    Lawrance, I.C.2
  • 55
    • 79953788656 scopus 로고    scopus 로고
    • Assessing response and loss of response to biological therapies in IBD
    • Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106(4):685-98.
    • (2011) Am J Gastroenterol , vol.106 , Issue.4 , pp. 685-698
    • Yanai, H.1    Hanauer, S.B.2
  • 57
  • 62
    • 0003059415 scopus 로고    scopus 로고
    • Infliximab for patients with refractory ulcerative colitis
    • Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001;7 Suppl 1:S30-3.
    • (2001) Inflamm Bowel Dis , vol.7 , Issue.SUPPL. 1
    • Chey, W.Y.1
  • 63
    • 0035905514 scopus 로고    scopus 로고
    • Infliximab in severe steroid-refractory ulcerative colitis: A pilot study
    • Kaser A, Mairinger T, Vogel W, Tilg H. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 2001;113(23-24):930-3.
    • (2001) Wien Klin Wochenschr , vol.113 , Issue.23-24 , pp. 930-933
    • Kaser, A.1    Mairinger, T.2    Vogel, W.3    Tilg, H.4
  • 65
    • 0036743233 scopus 로고    scopus 로고
    • Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: Result of an open study on 13 patients
    • Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 2002;34(9):626-30.
    • (2002) Dig Liver Dis , vol.34 , Issue.9 , pp. 626-630
    • Kohn, A.1    Prantera, C.2    Pera, A.3    Cosintino, R.4    Sostegni, R.5    Daperno, M.6
  • 66
    • 1242327175 scopus 로고    scopus 로고
    • Infliximab for acute severe ulcerative colitis: A randomized pilot study in non steroid refractory patients
    • Ochesenkuhn T, Sackmann M, Geoke B. Infliximab for acute severe ulcerative colitis: a randomized pilot study in non steroid refractory patients. Gastroenterology 2003;124(4 Suppl 1):A62.
    • (2003) Gastroenterology , vol.124 , Issue.4 SUPPL. 1
    • Ochesenkuhn, T.1    Sackmann, M.2    Geoke, B.3
  • 67
    • 79955550194 scopus 로고    scopus 로고
    • Future therapeutic approaches for inflammatory bowel diseases
    • Plevy SE, Targan SR. Future therapeutic approaches for inflammatory bowel diseases. Gastroenterology 2011;140(6):1838-46.
    • (2011) Gastroenterology , vol.140 , Issue.6 , pp. 1838-1846
    • Plevy, S.E.1    Targan, S.R.2
  • 68
    • 0038460945 scopus 로고    scopus 로고
    • Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A ran83domised controlled trial
    • Probert CS, Hearing SD, Schreiber S, Küühbacher T, Ghosh S, Arnott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a ran83domised controlled trial. Gut 2003;52(7):998-1002.
    • (2003) Gut , vol.52 , Issue.7 , pp. 998-1002
    • Probert, C.S.1    Hearing, S.D.2    Schreiber, S.3    Küühbacher, T.4    Ghosh, S.5    Arnott, I.D.6    Forbes, A.7
  • 70
    • 79751472562 scopus 로고    scopus 로고
    • The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: When to start, when to stop, which drug to choose, and how to predict response?
    • quiz 213
    • D'Haens G., Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer S., Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106(2):199-212;quiz 213.
    • (2011) Am J Gastroenterol , vol.106 , Issue.2 , pp. 199-212
    • D'Haens, G.1    Panaccione, R.2    Higgins, P.D.3    Vermeire, S.4    Gassull, M.5    Chowers, Y.6    Hanauer, S.7    Herfarth, H.8    Hommes, D.W.9    Kamm, M.10    Löfberg, R.11    Quary, A.12    Sands, B.13    Sood, A.14    Watermeyer, G.15


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.